Table 1 Patient characteristics ( N =146)
From: Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy
Patient characteristics at baseline | Values at baseline | Patient characteristics at follow-up | Values at follow-up |
|---|---|---|---|
Age (years), median (IQR) (N =146) | 68 (62 to 74) | Age (years), median (IQR) (N =146) | 71 (65 to 77) |
Baseline PSA (ng/mL), median (IQR) (N =146) | 72 (20 to 187) | Follow-up PSA (ng/mL), median (IQR) (N =146) | 23 (2.6 to 89) |
Baseline BSI (N =146) | Follow-up BSI (N =146) | ||
BSI =0 (M0), N (%) | 84 (57%) | BSI =0 (M0), N (%) | 55 (37%) |
BSI >0 (M1), N (%) | 62 (43%) | BSI >0 (M1), N (%) | 91 (63%) |
BSI >0, median (IQR) | 1.5 (0.2 to 4.2) | BSI >0, median (IQR) | 1.7 (0.3 to 4.9) |
Clinical T stage (N =131) | BSI change from baseline to follow-up (N =146) | ||
T1, N (%) | 9 (7%) | ||
T2, N (%) | 21 (16%) | ||
T3, N (%) | 85 (65%) | BSI increased: | |
T4, N (%) | 16 (12%) | High BSI change, N (%) | 67 (46%) |
Gleason score (N =135) | BSI unchanged/decreased: | ||
5, N (%) | 1 (0.7%) | Low BSI change, N (%) | 79 (54%) |
6, N (%) | 6 (4.3%) | ||
7, N (%) | 48 (36%) | ||
8, N (%) | 36 (26%) | ||
9, N (%) | 39 (29%) | ||
10, N (%) | 5 (4%) |